An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The purpose of this study is to investigate the effects of experimental medication BMS-986165 in healthy male participants.

Key facts

Study ID

NCT03660436

Run by

Bristol-Myers Squibb

People needed

131

Starts

2018-08-14

Expected to finish

2018-10-18

Last updated by the study team

2018-12-19

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy participant, as determined by no clinically significant deviation from normal in physical examination, electrocardiograms (ECGs), and clinical laboratory determinations
• Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
• Normal renal function at screening as evidenced by an estimated GFR (glomerular filtration rate) > 80 mL/min/1.732 m2

You may not qualify if…

• Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease
• Positive anti- John Cunningham virus (JCV) antibody test at Screening
• History of allergy to MMF, BMS-986165, related compounds or any significant drug allergy
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• PRA Health Sciences — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.